{
    "title": "103_hr1926",
    "content": "The \"National Narcotics Leadership Act Amendments of 1993\" allows the Director to request funding for specific initiatives in line with the President's priorities for the National Drug Control Strategy. SEC. 3. Report on Reprogramming; Office Personnel Restriction. The Director must report to Congress quarterly on any reprogramming of funds over $5,000,000 for National Drug Control Program activities. Additionally, Federal officers in the Office of National Drug Control Policy appointed by the President cannot engage in Federal election campaign activities. SEC. 4. National Drug Control Strategy Outcome Measures. Section 1005(a) of the National Narcotics Leadership Act of 1988 is amended to include an evaluation of Federal drug control effectiveness in the National Drug Control Strategy, assessing reduction of drug use in various populations and workplaces. The evaluation of Federal drug control effectiveness in the National Drug Control Strategy includes assessing the reduction of drug availability in the United States through various measures such as quantities of drugs available, drug seizures, cultivation and destruction of drug sources, and changes in drug prices and purity. The evaluation of Federal drug control effectiveness includes assessing the reduction of drug consequences, such as healthcare costs, drug-related crime, and contribution to the underground economy. The evaluation of drug treatment in the United States includes assessing public and private treatment capacity, availability of treatment on demand for specific groups, estimated number of drug users who could benefit from treatment, and the success of drug treatment programs. The Director is required to assess the quality of drug use measurement instruments, the coverage of national drug use measurement techniques, and the population at risk for drug use in the National Drug Control Strategy. The Director is mandated to assess drug use measurement instruments, national coverage of drug use measurement techniques, population at risk for drug use, actions to correct deficiencies, factors limiting treatment availability, and cooperation of federal agencies in collecting drug-related information. Additionally, the Director must report on drug use and availability in the US, effectiveness of interdiction and treatment in each National Drug Control Strategy. The Director is required to evaluate the effectiveness of interdiction, treatment, prevention, law enforcement, and international programs under the National Drug Control Strategy in reducing drug use and availability. The Director of the Office of National Drug Control Policy is added as a member of the National Security Council. Additionally, a Counter-Drug Technology Assessment Center is established. The National Narcotics Leadership Act of 1988 is amended to include support for drug treatment technology and assistance to the Office of National Drug Control Policy from the Advanced Research Project Agency. The National Narcotics Leadership Act of 1988 is amended by repealing and redesignating certain sections to follow section 1007. SEC. 7 amends the National Narcotics Leadership Act to allow the Director to pay for necessary expenses for consultation on the National Drug Control Strategy. SEC. 8 authorizes appropriations as needed for fiscal year 1994. SEC. 9 changes the termination date of the Office of National Drug Control Policy to September 30, 1994."
}